All of the following are FDA-approved indications for montelukast sodium, EXCEPT?

Montelukast sodium is a selective leukotriene receptor antagonist (LTRA) that blocks the action of cysteinyl leukotrienes (CysLT1). These inflammatory mediators are potent bronchoconstrictors and contributors to airway edema and mucus secretion. It is used as a maintenance therapy to prevent chronic respiratory symptoms. It is frequently prescribed for patients who have concomitant asthma and allergies. Rationale: A. Allergic rhinitis is an FDA-approved indication for montelukast. It is effective for both seasonal and perennial allergic rhinitis in adults and pediatric patients. It helps relieve symptoms such as nasal congestion, sneezing, and rhinorrhea by blocking leukotriene-mediated inflammation in the nasal mucosa and upper respiratory tract. B. Prevention of exercise-induced bronchoconstriction (EIB) is a specifically approved indication for montelukast. It is taken at least 2 hours before exercise to provide protection for up to 24 hours. This makes it an alternative for patients who do not achieve adequate control with short-acting beta agonists alone. C. Asthma is the primary FDA-approved indication for montelukast sodium. It is used for the long-term prophylaxis and chronic treatment of asthma in patients as young as 12 months. It helps reduce the frequency of asthma attacks but is never used to treat an acute exacerbation or status asthmaticus. D. COPD (Chronic Obstructive Pulmonary Disease) is not an FDA-approved indication for montelukast. While leukotrienes are present in COPD, clinical trials have not consistently shown that LTRAs provide significant benefit for airflow obstruction in this population. Maintenance of COPD typically relies on long-acting bronchodilators and inhaled corticosteroids instead.